Biodesix (BDSX)
Uses multi-omic testing to address clinical questions in lung disease.
Something off on this page? Send us feedback.
Lung diagnostic testing for healthcare providers and development services for biopharmaceutical customers generate revenue. A multi-omic approach addresses clinical questions in lung disease, with testing and services performed in Colorado and Kansas.
Blood-based, multi-omic tests address clinical questions in lung disease for healthcare providers. Lung diagnostic testing is one revenue source, alongside development services for biopharmaceutical customers.
Testing and services are performed in Louisville, Colorado, and De Soto, Kansas. The portfolio grew through the Integrated Diagnostics acquisition, including rights to the Nodify XL2 test, and the acquisition of Nodify CDT.
Commercial operations pair diagnostic testing with services for biopharmaceutical companies. The business focuses on clinical care and outcomes through multi-omic diagnostics, with testing and services performed in its Louisville and De Soto laboratories.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 10, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $27 | Target: $35 |
| Jun 24, 2026 | Roth Capital | Initiate | Rating: —Target: — | Target: $32 |
| Jun 18, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $20 | Target: $27 |
| Jun 15, 2026 | H.C. Wainwright | Target | Target: — | Target: $26 |
| Feb 27, 2026 | William Blair | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $30.0M · Total debt $71.8M · Total assets $95.3M · Shareholders' equity $9.1M
- Revenue
- $26.9M
- Operating income
- −$5.4M
- Net income
- −$7.3M
No dividends on record.
| Institutions | 38.69% | 4.08M shares | |
|---|---|---|---|
| 45 holders · as of Jun 30, 2026 | |||
| Insiders | 20.15% | 2.13M shares | |
| 13 holders · as of Aug 13, 2026 | |||
| Other | 41.16% | 4.34M shares | |
| remainder | |||
10.55M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (10.55M in the company's Sep 22, 2026 report, 8.14M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Orin HirschmanInsider | 7.19% | 758,328 | filed Apr 28, 2026 |
Aigh Capital Management LLCInstitution | 6.43% | 678,328 | as of Jun 30, 2026 |
Soleus Capital Management, L.P.Institution | 5.55% | 585,958 | as of Jun 30, 2026 |
Jack W. SchulerInsider10 percent owner, other: Emeritus Director | 5.27% | 555,810 | filed Aug 13, 2026 |
Soleus Capital Master Fund, L.P.Institution | 4.98% | 525,241 | filed Jun 18, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 12, 2026 | Jack W. Schuler | 10 percent owner, other: Emeritus Director | +15,000 | $24.47 |
| Aug 11, 2026 | Jack W. Schuler | 10 percent owner, other: Emeritus Director | +13,700 | $24.01 |
| Aug 10, 2026 | Jack W. Schuler | 10 percent owner, other: Emeritus Director | +13,900 | $24.25 |
| Feb 23, 2026 | Scott Hutton | director, officer: President & CEO | −1,490 | $12.78 |
| Feb 23, 2026 | Chris Vazquez | officer: Chief Accounting Officer | −211 | $12.78 |
- Guardant Health
Liquid-biopsy genomic profiling for treatment selection
- Tempus AI
Tumor profiling and molecular data services for oncology
- NeoGenomics
Oncology laboratory testing and tumor molecular profiling
- Veracyte
Genomic assessment of malignancy risk in lung nodules
- Adaptive Biotechnologies
Immune-repertoire profiling for cancer research
- Personalis
Cancer immunogenomics for biopharma research
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Biodesix | $28.17 | −0.91% | $231.4M | — | — | 2.2 | +34.2% |
| Guardant Health | $177.58 | +2.13% | $23.33B | — | — | 19.7 | +44.3% |
| Tempus AI | $77.66 | −0.47% | $13.67B | — | — | 9.5 | +21.6% |
| NeoGenomics | $19.13 | −1.42% | $498.7M | — | 68.8 | 0.7 | +11.2% |
| Veracyte | $42.90 | +3.32% | $3.31B | 29.7 | 23.6 | 5.9 | +15.5% |
| Adaptive Biotechnologies | $27.59 | −0.97% | $4.46B | — | — | 14.5 | +21.5% |
| Personalis | $16.30 | +0.37% | $1.73B | — | — | 24.9 | +30.0% |
| Median | 29.7 | 46.2 | 12.0 | +21.5% |